News & Events

HTG Molecular Diagnostics Expands Its IVD Agreement With Illumina to Increase the Number of Test Kits

HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, announced that it has amended and restated its IVD Test Development and Component Supply Agreement with Illumina to, among other things, extend the agreement term and increase the number of in-vitro diagnostic (IVD) test kits that may be developed for use with Illumina sequencing technology.

Read More

HTG Molecular Diagnostics Reports First Quarter 2017 Results

TUCSON, Ariz., May 15, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today reported financial results for the three months ended March 31, 2017.

Read More

HTG Molecular Diagnostics to Hold 2017 First Quarter Results Conference Call on May 15, 2017

TUCSON, Ariz., May 01, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that the Company will release 2017 first quarter results after market close on Monday, May 15, 2017. Company management will host an investment-community conference call beginning at 4:30pm Eastern Time on Monday, May 15 to discuss these results and answer questions.

Read More

HTG Molecular Diagnostics and Instituto Valenciano de Oncología Initiate Breast Cancer Recurrence Risk Collaboration

TUCSON, Ariz., April 24, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, announced that it has entered into a research collaboration agreement with Instituto Valenciano de Oncología (IVO). The initial project, utilizing the HTG EdgeSeq Oncology Biomarker Panel, will focus on the development and validation of a breast cancer recurrence risk score, based on genes that are differentially expressed between patients with low and high risk of recurrence.

Read More

HTG Molecular Diagnostics and Centre Léon Bérard Enter Into Molecular Profiling Research Agreement

TUCSON, Ariz., April 17, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, announced that it has entered into a research agreement with Centre Léon Bérard, which provides the framework for molecular profiling studies aimed to advance precision medicine. The initial project utilizes the HTG EdgeSeq Oncology Biomarker Panel to retrospectively characterize immunologic profiles from advanced malignant tumor samples collected in the ProfiLER study (ClinicalTrials.gov identifier NCT01774409).

Read More

HTG Molecular Diagnostics Transfers Listing to The Nasdaq Capital Market

TUCSON, Ariz., April 17, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, announced that, on April 12, 2017, the company received formal notice from The NASDAQ Stock Market LLC indicating that the Nasdaq Hearings Panel had granted the Company’s request to transfer the listing of HTG’s common stock from The Nasdaq Global Market to The Nasdaq Capital Market based upon HTG’s compliance with all requirements for continued listing on the latter market. The intra-market transfer took effect upon the open of trading this morning, Monday, April 17, 2017.

Read More

HTG Molecular Diagnostics and Daiichi Sankyo Complete Master Services Agreement

HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, announced that it has entered into a master services agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for work to be performed in HTG’s VERI/O laboratory.

Read More

HTG Molecular Diagnostics Completes Initial Technical Feasibility Testing with QIAGEN GeneReader NGS System

TUCSON, Ariz., March 23, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments, reagents, and services for molecular profiling applications, today announced that its HTG EdgeSeq technology has been successfully adapted for use with the QIAGEN GeneReader NGS System based on the results of initial technical feasibility tests. Results from samples tested with the HTG EdgeSeq DLBCL Cell of Origin Assay gene panel adapted for detection with the GeneReader NGS System showed strong correlation (r = 0.98) to data previously generated on the MiSeq sequencer.

Read More

HTG Molecular Diagnostics Reports Fourth Quarter and Full Year 2016 Results

TUCSON, Ariz., March 23, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today reported financial results for the fourth quarter and year ended December 31, 2016.

Read More

HTG Molecular Diagnostics Obtains CE Mark for its HTG EdgeSeq ALKPlus Assay EU

TUCSON, Ariz., March 22, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it has obtained CE marking in the European Union for its HTG EdgeSeq ALKPlus Assay EU.

The HTG EdgeSeq ALKPlus Assay EU is an in vitro diagnostic assay intended to measure and analyze mRNA ALK gene rearrangements in formalin-fixed, paraffin-embedded lung tumor specimens from patients previously diagnosed with non-small cell lung cancer (NSCLC). The assay may be used to aid in the identification of patients eligible for treatment with ALK-targeted therapeutics, such as crizotinib, and is automated on the HTG EdgeSeq system using a next-generation sequencer for detection.

Read More

HTG Molecular Diagnostics to Hold 2016 Fourth Quarter and Full Year Financial Results Conference Call on March 23, 2017

TUCSON, Ariz., March 21, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments, reagents, and services for molecular profiling applications, today announced that the Company will release 2016 fourth quarter and full year financial results after market close on Thursday, March 23, 2017. Company management will host an investment-community conference call beginning at 5:00pm Eastern Time on Thursday, March 23 to discuss these results and answer questions.

Read More

HTG Molecular Diagnostics Appoints New Chair of the Board of Directors

TUCSON, Ariz., March 07, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that Ann F. Hanham, Ph.D., a director since August 2016, has been appointed to the Chair of the company’s board of directors.

Read More